NCT07073833View on ClinicalTrials.gov

The Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 20, 2025

Primary Completion Date

July 30, 2027

Study Completion Date

July 30, 2028

Conditions
Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Interventions
DRUG

IBR900 cell injection

NK cells

DRUG

rituximab

CD20 antibody

Trial Locations (2)

Unknown

RECRUITING

The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

RECRUITING

Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Imbioray (Hangzhou) Biomedicine Co., Ltd.

INDUSTRY